000292457 001__ 292457
000292457 005__ 20240919150643.0
000292457 0247_ $$2doi$$a10.1093/jncics/pkae070
000292457 0247_ $$2pmid$$apmid:39180334
000292457 0247_ $$2altmetric$$aaltmetric:166701745
000292457 037__ $$aDKFZ-2024-01724
000292457 041__ $$aEnglish
000292457 082__ $$a610
000292457 1001_ $$aCariolou, Margarita$$b0
000292457 245__ $$aAdiposity assessed close to diagnosis and prostate cancer prognosis in the EPIC study.
000292457 260__ $$aOxford$$bOxford University Press$$c2024
000292457 3367_ $$2DRIVER$$aarticle
000292457 3367_ $$2DataCite$$aOutput Types/Journal article
000292457 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726751163_16238
000292457 3367_ $$2BibTeX$$aARTICLE
000292457 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292457 3367_ $$00$$2EndNote$$aJournal Article
000292457 500__ $$a2024 Sep 2;8(5):pkae070
000292457 520__ $$aAdiposity has been characterised as a modifiable risk factor of prostate cancer. Its association with outcomes after prostate cancer diagnosis, however, needs to be better understood and obtain more evidence to assist the development of lifestyle guidance for prostate cancer patients.We investigated the associations between adiposity indices close to prostate cancer diagnosis (up to two years pre- or up to five years post-diagnosis) and mortality in 1,968 men of the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Men were followed for a median of 9.5 years. Cox proportional-hazards models were adjusted for age and year of diagnosis, stage, grade, smoking and stratified by country.Each 5-unit increment in pre- or post-diagnosis body mass index (BMI) combined was associated with a 30% higher rate of all-cause and a 49% higher rate of prostate cancer-specific mortality. Similarly, each 5-unit increment in pre-diagnosis BMI was associated with a 35% higher rate of all-cause and a 51% higher rate of prostate cancer-specific mortality. The associations were less strong for post-diagnosis BMI with a lower number of men in analyses. Less clear positive associations were shown for waist circumference, hip circumference, and waist-to-hip ratio but data was limited.Elevated levels of adiposity close to prostate cancer diagnosis could lead to higher risk of mortality; therefore, men are encouraged to maintain a healthy weight. Additional research is needed to confirm if excessive adiposity after prostate cancer diagnosis could worsen prognosis.
000292457 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000292457 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292457 650_7 $$2Other$$aadiposity
000292457 650_7 $$2Other$$alifestyle
000292457 650_7 $$2Other$$amortality
000292457 650_7 $$2Other$$aprostate cancer
000292457 650_7 $$2Other$$asurvival
000292457 7001_ $$aChristakoudi, Sofia$$b1
000292457 7001_ $$aGunter, Marc J$$b2
000292457 7001_ $$aKey, Tim$$b3
000292457 7001_ $$aPérez-Cornago, Aurora$$b4
000292457 7001_ $$aTravis, Ruth$$b5
000292457 7001_ $$aZamora-Ros, Raul$$b6
000292457 7001_ $$aPetersen, Kristina Elin T$$b7
000292457 7001_ $$aTjønneland, Anne$$b8
000292457 7001_ $$aWeiderpass, Elisabete$$b9
000292457 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b10$$udkfz
000292457 7001_ $$0P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aSeibold, Petra$$b11$$udkfz
000292457 7001_ $$aInan-Eroglu, Elif$$b12
000292457 7001_ $$aSchulze, Matthias B$$b13
000292457 7001_ $$aMasala, Giovanna$$b14
000292457 7001_ $$aAgnoli, Claudia$$b15
000292457 7001_ $$aTumino, Rosario$$b16
000292457 7001_ $$aDi Girolamo, Chiara$$b17
000292457 7001_ $$aAizpurua, Amaia$$b18
000292457 7001_ $$aRodriguez-Barranco, Miguel$$b19
000292457 7001_ $$aSantiuste, Carmen$$b20
000292457 7001_ $$aGuevara, Marcela$$b21
000292457 7001_ $$aAune, Dagfinn$$b22
000292457 7001_ $$aChan, Doris Sm$$b23
000292457 7001_ $$aMuller, David C$$b24
000292457 7001_ $$aTsilidis, Konstantinos K$$b25
000292457 773__ $$0PERI:(DE-600)2975772-1$$a10.1093/jncics/pkae070$$gp. pkae070$$n5$$ppkae070$$tJNCI cancer spectrum$$v8$$x2515-5091$$y2024
000292457 909CO $$ooai:inrepo02.dkfz.de:292457$$pVDB
000292457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000292457 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fd17a8dbf8d08ea5bb656dfef7398215$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000292457 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000292457 9141_ $$y2024
000292457 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI CANCER SPECT : 2022$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-09-22T16:36:51Z
000292457 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-09-22T16:36:51Z
000292457 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-09-22T16:36:51Z
000292457 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-10-27
000292457 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-10-27
000292457 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000292457 980__ $$ajournal
000292457 980__ $$aVDB
000292457 980__ $$aI:(DE-He78)C020-20160331
000292457 980__ $$aUNRESTRICTED